Clinical commentary highlights frequent biologic therapy interruption and subsequent relapse patterns in psoriasis, indicating critical challenges for long-term disease management.
Highly effective biologic therapies have transformed the management of moderate-to-severe psoriasis, making complete or near-complete skin clearance an achievable treatment goal.Despite these advances, treatment interruptions remain frequent in clinical practice for various reasons.Recent real-world data show that therapy cessation is common, with approximately half of patients discontinuing biologic treatment within 1 year [1].In this issue of the International Journal of Dermatology, Aydemir and Kundakcı provide valuable recent evidence from clinical practice on relapse following biologic interruption and subsequent treatment re-initiation [2].
No takes yet. Share an insight, caveat, or question.
Lomicová et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: